Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on July 30, 2009

Stroke. 2009
Published online before print July 30, 2009, doi: 10.1161/STROKEAHA.108.544395
A more recent version of this article appeared on October 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/10/3384    most recent
STROKEAHA.108.544395v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Karki, K.
Right arrow Articles by Seyfried, D. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karki, K.
Right arrow Articles by Seyfried, D. M.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Aneurysm, AVM, hematoma

Submitted on March 18, 2009
Revised on June 16, 2009
Accepted on June 17, 2009

Simvastatin and Atorvastatin Improve Neurological Outcome After Experimental Intracerebral Hemorrhage

Kishor Karki PhD; Robert A. Knight PhD; Yuxia Han BS; Dongmei Yang MD; Jianfeng Zhang MS; Karyn A. Ledbetter BS; Michael Chopp PhD; and Donald M. Seyfried MD*

From the Departments of Neurology (K.K., R.A.K., K.A.L., M.C.) and Neurosurgery (Y.H., D.Y., J.Z., D.M.S.), Henry Ford Hospital, Detroit, Mich; and the Department of Physics (K.K., R.A.K., M.C.), Oakland University, Rochester, Mich.

* To whom correspondence should be addressed. E-mail: nsdos{at}neuro.hfh.edu.

Background and Purpose—This study investigates the effects of statin treatment on experimental intracerebral hemorrhage (ICH) using behavioral, histological, and MRI measures of recovery.

Methods—Primary ICH was induced in rats. Simvastatin (2 mg/kg), atorvastatin (2 mg/kg), or phosphate-buffered saline (n=6 per group) was given daily for 1 week. MRI studies were performed 2 to 3 days before ICH, and at 1 to 2 hours and 1, 2, 7, 14, and 28 days after ICH. The ICH evolution was assessed via hematoma volume measurements using susceptibility-weighted imaging (SWI) and tissue loss using T2 maps and hematoxylin and eosin (H&E) histology. Neurobehavioral tests were done before ICH and at various time points post-ICH. Additional histological measures were performed with doublecortin neuronal nuclei and bromodeoxyuridine stainings.

Results—Initial ICH volumes determined by SWI were similar across all groups. Simvastatin significantly reduced hematoma volume at 4 weeks (P=0.002 versus control with acute volumes as baseline), whereas that for atorvastatin was marginal (P=0.09). MRI estimates of tissue loss (% of contralateral hemisphere) for treated rats were significantly lower (P=0.0003 and 0.001, respectively) than for control at 4 weeks. Similar results were obtained for H&E histology (P=0.0003 and 0.02, respectively). Tissue loss estimates between MRI and histology were well correlated (R2=0.764, P<0.0001). Significant improvement in neurological function was seen 2 to 4 weeks post-ICH with increased neurogenesis observed.

Conclusions—Simvastatin and atorvastatin significantly improved neurological recovery, decreased tissue loss, and increased neurogenesis when administered for 1 week after ICH.


Key words: hematoma • statin • MRI • SWI • rat